Current Report Filing (8-k)
January 07 2019 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 31, 2018
|
INNOVATION PHARMACEUTICALS INC.
|
|
(Exact Name of Registrant as Specified in Charter)
|
|
Nevada
|
|
001-37357
|
|
30-0565645
|
|
(State or Other Jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
|
of Incorporation)
|
|
|
|
Identification No.)
|
|
100 Cummings Center, Suite 151-B Beverly, Massachusetts
|
|
01915
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(978) 921-4125
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On December 31, 2018, Mark R. Tobin resigned from his position as a director of Innovation Pharmaceuticals Inc. (the “Company”), effective immediately. Given the increased demands of his full-time job, Mr. Tobin does not have the time necessary to devote to the Company to fill the position of director. His resignation was not a result of any disagreement with the Company.
On January 7, 2019, Arthur P. Bertolino, MD, PhD, MBA, the Company’s President and Chief Medical Officer, joined the Board of Directors. The Company is currently exploring options for further Board additions in preparation for late-stage clinical trials and ongoing portfolio development.
There are no related party transactions between the Company and Dr. Bertolino that would require disclosure under Item 404(a) of Regulation S-K. A description of Dr. Bertolino’s compensation for his service as President and Chief Medical Officer of the Company is set forth under Item 11 of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 11, 2018. Dr. Bertolino will not receive any additional compensation for his service on the Board of Directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
INNOVATION PHARMACEUTICALS INC.
|
|
|
|
|
|
Dated: January 7, 2019
|
By:
|
/s/ Leo Ehrlich
|
|
|
|
Name:
|
Leo Ehrlich
|
|
|
|
Title:
|
Chief Executive Officer and Chief Financial Officer
|
|
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024
